Elzovantinib

Elzovantinib, also known as TPX-0022 and CSF1R-IN-2, is an orally bioavailable CSF1R inhibitor with a novel three-dimensional macrocyclic structure that inhibits the MET, CSF1R (colony stimulating factor 1 receptor) and SRC kinases. Targeting CSF1R leads to the modulation of tumor-associated macrophages (TAMs), a type of immune cell that suppresses the T-cell mediated anti-tumor immune response. Inhibition of CSF1R with TPX-0022 is a promising therapeutic strategy as a single agent or in combination with standard of care chemotherapy and immunotherapy in various solid tumors. vantinib, also known as TPX-0022 and CSF1R-IN-2, is an orally bioavailable CSF1R inhibitor with a novel three-dimensional macrocyclic structure that inhibits the MET, CSF1R (colony stimulating factor 1 receptor) and SRC kinases. Targeting CSF1R leads to the modulation of tumor-associated macrophages (TAMs), a type of immune cell that suppresses the T-cell mediated anti-tumor immune response. Inhibition of CSF1R with TPX-0022 is a promising therapeutic strategy as a single agent or in combination with standard of care chemotherapy and immunotherapy in various solid tumors.